Last reviewed · How we verify

KETOPROFEN(RP19583)

Sanofi · Phase 3 active Small molecule

KETOPROFEN(RP19583) is a Nonsteroidal anti-inflammatory drug (NSAID) Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Acute and chronic pain, Rheumatoid arthritis, Osteoarthritis.

Ketoprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Ketoprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. Used for Acute and chronic pain, Rheumatoid arthritis, Osteoarthritis.

At a glance

Generic nameKETOPROFEN(RP19583)
SponsorSanofi
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCOX-1, COX-2
ModalitySmall molecule
Therapeutic areaPain Management, Rheumatology, Inflammation
PhasePhase 3

Mechanism of action

As a nonsteroidal anti-inflammatory drug (NSAID), ketoprofen blocks both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammatory responses and pain signaling. By reducing prostaglandin levels, the drug provides analgesic, anti-inflammatory, and antipyretic effects. RP19583 likely represents a specific formulation or modified-release variant of ketoprofen designed to optimize therapeutic delivery.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about KETOPROFEN(RP19583)

What is KETOPROFEN(RP19583)?

KETOPROFEN(RP19583) is a Nonsteroidal anti-inflammatory drug (NSAID) drug developed by Sanofi, indicated for Acute and chronic pain, Rheumatoid arthritis, Osteoarthritis.

How does KETOPROFEN(RP19583) work?

Ketoprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

What is KETOPROFEN(RP19583) used for?

KETOPROFEN(RP19583) is indicated for Acute and chronic pain, Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis.

Who makes KETOPROFEN(RP19583)?

KETOPROFEN(RP19583) is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What drug class is KETOPROFEN(RP19583) in?

KETOPROFEN(RP19583) belongs to the Nonsteroidal anti-inflammatory drug (NSAID) class. See all Nonsteroidal anti-inflammatory drug (NSAID) drugs at /class/nonsteroidal-anti-inflammatory-drug-nsaid.

What development phase is KETOPROFEN(RP19583) in?

KETOPROFEN(RP19583) is in Phase 3.

What are the side effects of KETOPROFEN(RP19583)?

Common side effects of KETOPROFEN(RP19583) include Gastrointestinal upset (dyspepsia, nausea), Abdominal pain, Headache, Dizziness, Gastrointestinal bleeding (serious), Cardiovascular events (serious).

What does KETOPROFEN(RP19583) target?

KETOPROFEN(RP19583) targets COX-1, COX-2 and is a Nonsteroidal anti-inflammatory drug (NSAID).

Related